α-Lipoic Acid Antioxidant Treatment Limits Glaucoma-Related Retinal Ganglion Cell Death and Dysfunction

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Inman, Denise M ^a,c   Lambert, Wendi S ^b   Calkins, David J ^b   Horner, Philip J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; THIOCTIC ACID; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANTIOXIDANT; IMMUNOGLOBULIN RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; NOS2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DNA METABOLISM; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GLAUCOMA; LIPID PEROXIDATION; MOUSE; NERVE CELL NECROSIS; NERVE FIBER TRANSPORT; NITROSYLATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; RETINA GANGLION CELL; UPREGULATION; ANIMAL; C57BL MOUSE; CELL DEATH; DBA MOUSE; DIET SUPPLEMENTATION; DNA DAMAGE; DRUG EFFECTS; DRUG SCREENING; INTRAOCULAR PRESSURE; METABOLISM; NERVE DEGENERATION; NERVE FIBER; ORAL DRUG ADMINISTRATION; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY; RETINA; TREATMENT OUTCOME;

MUS;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; AXONS; CELL DEATH; DIETARY SUPPLEMENTS; DNA DAMAGE; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GLAUCOMA; INTRAOCULAR PRESSURE; LIPID PEROXIDATION; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NERVE DEGENERATION; NITRIC OXIDE SYNTHASE TYPE II; OXIDATION-REDUCTION; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; RETINA; RETINAL GANGLION CELLS; THIOCTIC ACID; TREATMENT OUTCOME; UP-REGULATION;

EID: 84878766975     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065389     Document Type: Article

References (69)

1. Wei Y-H, Lee H-C, (2002) Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Experimental biology and medicine 227: 671-682.
2. Floyd RA, Hensley K, (2002) Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 23: 795-807.
3. Papadopoulos MC, Koumenis IL, Yuan TY, Giffard RG, (1998) Increasing vulnerability of astrocytes to oxidative injury with age despite constant antioxidant defenses. Neuroscience 82: 915-925.
4. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (New York, NY) 290: 985-989.
5. Tezel G, Yang X, Cai J, (2005) Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma. Invest Ophthalmol Vis Sci 46: 3177-3187.
6. Feilchenfeld Z, Yücel YH, Gupta N, (2008) Oxidative injury to blood vessels and glia of the pre-laminar optic nerve head in human glaucoma. Experimental eye research 87: 409-414 doi:10.1016/j.exer.2008.07.011.
7. Javadiyan S, Burdon KP, Whiting MJ, Abhary S, Straga T, et al. (2012) Elevation of serum asymmetrical and symmetrical dimethylarginine in patients with advanced glaucoma. Investigative ophthalmology & visual science 53: 1923-1927 doi:10.1167/iovs.11-8420.
8. Yildirim O, Ates NA, Ercan B, Muslu N, Unlu A, et al. (2005) Role of oxidative stress enzymes in open-angle glaucoma. Eye (Lond) 19: 580-583.
9. Sacca SC, Pascotto A, Camicione P, Capris P, Izzotti A, (2005) Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol 123: 458-463.
10. Moreno MC, Campanelli J, Sande P, Sáenz DA, Keller Sarmiento MI, et al. (2004) Retinal Oxidative Stress Induced by High Intraocular Pressure. Free Radical Biology and Medicine 37: 803-812 doi:10.1016/j.freeradbiomed.2004.06.001.
11. Ko M-L, Peng P-H, Ma M-C, Ritch R, Chen C-F, (2005) Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma. Free radical biology & medicine 39: 365-373 doi:10.1016/j.freeradbiomed.2005.03.025.
12. Lambert WS, Knox JM, Steele M, Bosco A, Wu G, et al. (2008) Dietary lipoic acid attenuates oxidative stress and retinal ganglion cell loss in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci 49: E-Abstract 5498.
13. Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF, (2004) Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol 137: 62-69.
14. Shih AY, Imbeault S, Barakauskas V, Erb H, Jiang L, et al. (2005) Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem 280: 22925-22936.
15. Qi X, Sun L, Lewin AS, Hauswirth WW, Guy J, (2007) Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy. Invest Ophthalmol Vis Sci 48: 5360-5370.
16. Shih AY, Li P, Murphy TH, (2005) A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J Neurosci 25: 10321-10335 doi:10.1523/JNEUROSCI.4014-05.2005.
17. Chidlow G, Schmidt KG, Wood JP, Melena J, Osborne NN, (2002) Alpha-lipoic acid protects the retina against ischemia-reperfusion. Neuropharmacology 43: 1015-1025 doi:12423671.
18. AREDS, Group AEDSR, (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119: 1417-1436 doi:10.1016/j.bbi.2008.05.010.
19. Gionfriddo JR, Freeman KS, Groth A, Scofield VL, Alyahya K, et al. (2009) alpha-Luminol prevents decreases in glutamate, glutathione, and glutamine synthetase in the retinas of glaucomatous DBA/2J mice. Vet Ophthalmol 12: 325-332.
20. Hirooka K, Tokuda M, Miyamoto O, Itano T, Baba T, et al. (2004) The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Current Eye Research 28: 153-157.
21. Luna C, Li G, Liton PB, Qiu J, Epstein DL, et al. (2009) Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 47: 198-204 doi:10.1016/j.fct.2008.10.029.
22. Schuettauf F, Quinto K, Naskar R, Zurakowski D, (2002) Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model. Vision Res 42: 2333-2337.
23. Ward MS, Khoobehi A, Lavik EB, Langer R, Young MJ (2006) Neuroprotection of Retinal Ganglion Cells in DBA/ 2J Mice With GDNF-Loaded Biodegradable Microspheres: 1-11. doi:10.1002/jps.
24. Sullivan T a, Geisert EE, Hines-Beard J, Rex TS, (2011) Systemic adeno-associated virus-mediated gene therapy preserves retinal ganglion cells and visual function in DBA/2J glaucomatous mice. Human gene therapy 22: 1191-1200 doi:10.1089/hum.2011.052.
25. Zhong L, Bradley J, Schubert W, Ahmed E, Adamis AP, et al. (2007) Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci 48: 1212-1218.
26. Zhou X, Li F, Ge J, Jr SRS, Tomita H, et al. (2007) Retinal Ganglion Cell Protection by 17-b-Estradiol in a Mouse Model of Inherited Glaucoma. doi:10.1002/dneu.
27. Smith AR, Shenvi S V, Widlansky M, Suh JH, Hagen TM, (2004) Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 11: 1135-1146.
28. Biewenga G, Haenen G, Bast A (1997) The Pharmacology of the Antioxidant Lipoic Acid: 315-331.
29. Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, et al. (1999) Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 31: 171-179.
30. Santos J dos, Kowluru R (2011) Role of Mitochondria Biogenesis in the Metabolic Memory Associated with the Continued Progression of Diabetic Retinopathy and Its Regulation by Lipoic Acid. Investigative Ophthalmology & Visual Science: 1-38.
31. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, et al. (1995) Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid: A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 38: 1425-1433.
32. Ziegler D, (2004) Thioctic Acid for Patients with Symptomatic Diabetic Polyneuropathy: A Critical Review. Treatments in Endocrinology 3: 173-189.
33. Chang B, Smith RS, Hawes NL, Anderson MG, Zabaleta A, et al. (1999) Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice. Nat Genet 21: 405-409.
34. Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, et al. (2002) Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat Genet 30: 81-85.
35. Cremer DR, Rabeler R, Roberts A, Lynch B, (2006) Long-term safety of alpha-lipoic acid (ALA) consumption: A 2-year study. Regul Toxicol Pharmacol 46: 193-201.
36. Rozen S, Skaletsky H, (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386.
37. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: 1-12.
38. Buckingham BP, Inman DM, Lambert WS, Oglesby E, Calkins DJ, et al. (2008) Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci 28: 2735-2744 doi:18337403.
39. Inman DM, Sappington RM, Horner PJ, Calkins DJ, (2006) Quantitative correlation of optic nerve pathology with ocular pressure and corneal thickness in the DBA/2 mouse model of glaucoma. Investigative ophthalmology & visual science 47: 986-996 doi:10.1167/iovs.05-0925.
40. Chauhan BC, Levatte TL, Garnier KL, Tremblay F, Pang I-H, et al. (2006) Semiquantitative optic nerve grading scheme for determining axonal loss in experimental optic neuropathy. Investigative ophthalmology & visual science 47: 634-640 doi:10.1167/iovs.05-1206.
41. Inman DM, Horner PJ, (2007) Reactive non-proliferative gliosis predominates in a chronic mouse model of glaucoma. Glia 55: 942-953.
42. Inoue K, Akaike T, Miyamoto Y, Okamoto T, Sawa T, et al. (1999) Nitrosothiol formation catalyzed by ceruloplasmin. Implication for cytoprotective mechanism in vivo. J Biol Chem 274: 27069-27075.
43. Arai-Gaun S, Katai N, Kikuchi T, Kurokawa T, Ohta K, et al. (2004) Heme oxygenase-1 induced in muller cells plays a protective role in retinal ischemia-reperfusion injury in rats. Investigative ophthalmology & visual science 45: 4226-4232 doi:10.1167/iovs.04-0450.
44. Schipper HM, (2004) Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Res Rev 3: 265-301.
45. Chen H, Weber AJ, (2004) Brain-derived neurotrophic factor reduces TrkB protein and mRNA in the normal retina and following optic nerve crush in adult rats. Brain Res 1011: 99-106.
46. Yan SD, Schmidt a M, Anderson GM, Zhang J, Brett J, et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. The Journal of biological chemistry 269: 9889-9897.
47. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss R a, et al. (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. The Journal of biological chemistry 272: 17810-17814.
48. Beckman JS, Koppenol WH, (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271: C1424-37.
49. Radi R, (2004) Nitric oxide, oxidants, and protein tyrosine nitration. Proceedings of the National Academy of Sciences of the United States of America 101: 4003-4008 doi:10.1073/pnas.0307446101.
50. Bosco A, Steele MR, Vetter ML, (2011) Early microglia activation in a mouse model of chronic glaucoma. J Comp Neurol 519: 599-620.
51. Steele MR, Inman DM, Calkins DJ, Horner PJ, Vetter ML, (2006) Microarray Analysis of Retinal Gene Expression in the DBA/2J Model of Glaucoma. Invest Ophthalmol Vis Sci 47: 977-985.
52. Kobayashi A, Ohta T, Yamamoto M, (2004) Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes. Methods Enzymol 378: 273-286.
53. Onouchi H, Ishii T, Miyazawa M, Uchino Y, Yasuda K, et al. (2012) Mitochondrial Superoxide Anion Overproduction in Tet-mev-1 Transgenic Mice Accelerates Age-Dependent Corneal Cell Dysfunctions. Invest Ophthalmol Vis Sci doi: 10.11.
54. John SW, Smith RS, Savinova O V, Hawes NL, Chang B, et al. (1998) Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Invest Ophthalmol Vis Sci 39: 951-962.
55. Ristow M, Zarse K, Oberbach A, Klöting N, Birringer M, et al. (2009) Antioxidants prevent health-promoting effects of physical exercise in humans. Proceedings of the National Academy of Sciences of the United States of America 106: 8665-8670 doi:10.1073/pnas.0903485106.
56. Ristow M, Schmeisser S, (2011) Extending life span by increasing oxidative stress. Free radical biology & medicine 51: 327-336 doi:10.1016/j.freeradbiomed.2011.05.010.
57. Shih AY, Erb H, Sun X, Toda S, Kalivas PW, et al. (2006) Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. J Neurosci 26: 10514-10523.
58. Chen F, Castranova V, Shi X, Demers LM, (1999) New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45: 7-17.
59. Bosco A, Inman DM, Steele MR, Wu G, Marsh-Armstrong N, et al. (2008) Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci 49: 1437-1446 doi:18385061.
60. Kim J, Cha Y-N, Surh Y-J, (2010) A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutation research 690: 12-23 doi:10.1016/j.mrfmmm.2009.09.007.
61. Connelly L, Palacios-Callender M, Ameixa C, Moncada S, Hobbs a J, (2001) Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. Journal of immunology 166: 3873-3881.
62. Aslan M, Yücel I, Akar Y, Yücel G, Ciftçioǧlu MA, et al. (2006) Nitrotyrosine formation and apoptosis in rat models of ocular injury. Free radical research 40: 147-153 doi:10.1080/10715760500456219.
63. Libby RT, Howell GR, Pang IH, Savinova OV, Mehalow AK, et al. (2007) Inducible nitric oxide synthase, Nos2, does not mediate optic neuropathy and retinopathy in the DBA/2J glaucoma model. BMC Neurosci 8: 108.
64. Underwood BR, Imarisio S, Fleming A, Rose C, Krishna G, et al. (2010) Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease. Human molecular genetics 19: 3413-3429 doi:10.1093/hmg/ddq253.
65. Liu Y, Schubert DR, (2009) The specificity of neuroprotection by antioxidants. Journal of biomedical science 16: 98 doi:10.1186/1423-0127-16-98.
66. Mohan Rema, Mohan V, Bhaskar A, Shanmugasundaram KR, (1995) Does oxidant stress play a role in diabetic retinopathy? Indian Journal of Ophthalmology 43: 17-21.
67. Van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, et al. (2008) Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 45: 1729-1737 doi:10.1016/j.freeradbiomed.2008.09.023.
68. Wong AA, Brown RE, (2012) A neurobehavioral analysis of the prevention of visual impairment in the DBA/2J mouse model of glaucoma. Investigative ophthalmology & visual science 53: 5956-5966 doi:10.1167/iovs.12-10020.
69. Baltan S, Inman DM, Danilov C, Morrison RM, Calkins DJ, et al. (2010) Metabolic vulnerability disposes retinal ganglion cell axons to dysfunction in a model of glaucomatous degeneration. J Neurosci 30: 5644-5652.